Liu R, Ginn SL, Lek M, North KN, Alexander IE, Little DG, Schindeler A. Myoblast sensitivity and fibroblast insensitivity to osteogenic conversion by BMP-2 correlates with the expression of Bmpr-1a. BMC Musculoskeletal Disorders. 2009; 15:51-61.

Schindeler A, Liu R, Little DG. The contribution of different cell lineages to bone repair: exploring a role for muscle stem cells. Differentiation. 2009; 77:12–18.

Schindeler A, McDonald MM, Bokko P, Little DG. Bone remodeling during fracture repair: the cellular picture. Sem Cell Dev Biol. 2008; 19(5):459-466.

Yu NY, Ruys AJ, Zenios M, Godfrey C, McDonald M, Kiely P, Mikulec K, Little DG, Schindeler A. Bisphosphonate-laden acrylic bone cement: mechanical properties, elution performance, and in vivo activity. J Biomed Mater Res B Appl Biomater. 2008; 87:482-91.

Amanat N, He LH, Swain MV, Little DG. The effect of zoledronic acid on the intrinsic material properties of healing bone: an indentation study. Med Eng Phys. 2008; 30:843-7.

McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG. Bolus or Weekly Zoledronic Acid Administration does not Delay Endochondral Fracture Repair but Weekly dosing enhances delays in Hard Callus Remodeling. Bone. 2008; 43:653-62.

Schindeler A, Morse A, Harry L, Godfrey C, Mikulec K, McDonald M, Gasser JA, Little DG. Models of tibial fracture healing in normal and Nf1-deficient mice. J Orthop Res. 2008; 26:1053-60.

Schindeler A, Little DG. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone. 2008; 42(4):616-22.

Schindeler A, Ramachandran M, Godfrey C, Morse A, McDonald M, Mikulec K, Little DG. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. J Orthop Res. 2008;26:65-74.

Nelson D, Zenios M, Ward K, Ramachandran M, Little DG. The deformity index as a predictor of final radiological outcome in Perthes' disease. J Bone Joint Surg Br. 2007; 89:1369-74.

Munns CF, Rajab MH, Hong J, Briody J, Hogler W, McQuade M, Little DG, Cowell CT. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone. 2007; 41:366-70

Ramachandran M, Ward K, Brown RR Munns CF, Cowell CT, Little DG. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents: a prospective case series. J Bone Joint Surg Am 2007; 89:1727-34

Schindeler A, Little DG. Bisphosphonate action: Revelations and deceptions from in vitro studies. J Pharm Sci. 2007; 96:1872-8.

Kiely P, Ward K, Bellmore MC, Cowell CT, Little DG. Bisphosphonate rescue in distraction osteogenesis: a case series. J Pediatr Orthop 2007; 27:467-71.

Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG. Decreased bone mineral density in type 1 neurofibromatosis: results from a pediatric cohort. J Pediatr Orthop. 2007; 27:472-5.

Amanat N, McDonald M, Godfrey C, Bilston L, Little DG. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 2007:22; 867-876

Little DG, Ramachandran M, Schindeler A. The anabolic and catabolic responses in bone repair: insights for biological and pharmacological intervention. J Bone Joint Surg Br 2007; 89-B:425-433

Kumar V, Kumar D, Howman-Giles RB, Little DG. Is 99mTc-labelled pamidronate a better agent than 99mTc-medronate for bone imaging? Nucl Med Commun. 2007; 28:101-107.

Schindeler A, Little DG. Ras-MAPK Signaling in Osteogenic Differentiation: Friend or Foe? J Bone Miner Res. 2006; 21:1331-8.